MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds on the issuance
of convertible...
$42,606K
Net cash provided by
financing activities
$27,737K
Effect of exchange rate
on cash, cash...
$5,925K
Canceled cashflow
$14,869K
Net decrease in
cash, cash...
-$289,240K
Canceled cashflow
$33,662K
Net income (loss)
$440,302K
Impairment of assets held
for sale
$97,845K
Accounts receivable,
prepaid expenses, and...
-$61,040K
Stock-based compensation
$36,015K
Loss on debt
extinguishment
-$28,714K
Depreciation and
amortization
$27,613K
Other items, net
-$5,756K
Impairment of other
long-lived assets
$4,880K
Provision for excess and
obsolete inventory
$1,945K
Proceeds from maturities
of marketable...
$353,735K
Proceeds from assets held
for sale
$19,653K
Finance lease payments
$10,071K
Proceeds from the
exercise of stock-based...
-$4,798K
Net cash used in
operating activities
-$244,635K
Net cash used in
investing activities
-$78,267K
Canceled cashflow
$704,110K
Canceled cashflow
$373,388K
Deferred revenue
-$622,939K
Purchases of marketable
securities
$445,267K
Accounts payable,
accrued expenses, and...
-$322,566K
Inventory
$3,240K
Capital expenditures
$5,560K
Internal-use software
$828K
Back
Back
Cash Flow
source: myfinsight.com
NOVAVAX INC (NVAX)
NOVAVAX INC (NVAX)